Cost-Savings from Conversion from Reference Pegfilgrastim with On-Body Injector Device to Biosimilar Pegfilgrastim-jmdb in DLBCL

2020 Year in Review - Biosimilars

Simulation-modeling data demonstrate significant cost-savings by converting from reference pegfilgrastim with on-body injector to biosimilar pegfilgrastim-jmdb for prophylaxis of chemotherapy-induced neutropenia/febrile neutropenia in patients with diffuse large B-cell lymphoma (DLBCL).

Reference pegfilgrastim with on-body injector (PEG-OBI) is more convenient than use of next-day prefilled syringes for the prophylaxis of chemotherapy-induced neutropenia (CIN)/febrile neutropenia (FN); however, the failure rate of PEG-OBI is in the range of 1.7% to 6.9%, which increases the risk for CIN/FN episodes and resultant FN-related hospitalizations. In this context, significant cost-savings may be achieved by converting from reference PEG-OBI to its biosimilar pegfilgrastim-jmdb (PEG-jmdb) administered using a next-day prefilled syringe that provides assured prophylaxis for CIN/FN. These cost-savings generated from assured prophylaxis with biosimilar PEG-jmdb may be reallocated to provide additional CIN/FN prophylaxis with PEG-jmdb or additional cycles of immunochemotherapy with rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). To test these hypotheses, simulation modeling of cost-efficiency and expanded access was conducted in a large hypothetical cohort of patients with diffuse large B-cell lymphoma (DLBCL); results of these analyses were reported at the 62nd American Society of Hematology Annual Meeting and Exposition.

A panel of 15,000 hypothetical patients with DLBCL who received 1 to 6 cycles of R-CHOP and were at increased risk for CIN/FN were included in the simulation modeling. Conversion rates from reference PEG-OBI to biosimilar PEG-jmdb that were used in the analysis ranged from 10% to 100%. Medication costs were based on second-quarter 2020 average sales price derived from the Centers for Medicare & Medicaid Services (CMS) fourth-quarter 2020 reimbursement limits. The administration costs of PEG-OBI and PEG-jmdb were derived from the CMS Outpatient Prospective Payment System. Reported PEG-OBI failure rates of 1% to 7% were utilized in the model. Based on published data, a 10.03% differential base rate of FN-related hospitalizations in non-Hodgkin lymphoma (NHL) over a 6-cycle regimen was used; the rate of FN-related hospitalizations was calculated as the rate without colony-stimulating factor (CSF) minus the rate with CSF.

For prophylaxis in 1 cycle of chemotherapy in a panel of 15,000 patients with DLBCL, cost-savings from conversion to PEG-jmdb ranged from $481,259 at 10% conversion to $4.8 million at 100% conversion, including cost of medication plus administration. Across 6 cycles of chemotherapy, cost-savings from conversion to PEG-jmdb ranged from $2.8 million at 10% conversion to $28.8 million at 100% conversion. These cost-savings may provide budget-neutral expanded access to purchase additional cycles of PEG-jmdb, 153 cycles (1 cycle at 10% conversion) and 9191 cycles (6 cycles at 100%). Alternatively, a minimum of 74 additional cycles of R-CHOP (1 cycle at 10% conversion) and a maximum of 4463 cycles (6 cycles at 100%) may also be purchased with the cost-savings.

Adjusting for PEG-OBI failures and associated hospitalization costs, cost-savings translated into expanded access to 15 additional cycles of PEG-jmdb or 7 cycles of R-CHOP (at 10% conversion and 1% PEG-OBI failure) and 1070 cycles of PEG-jmdb or 519 cycles of R-CHOP (at 100% conversion and 7% PEG-OBI failure).

These simulation models show significant cost-savings achieved through conversion from PEG-OBI to biosimilar PEG-jmdb for CIN/FN prophylaxis in patients with DLBCL when considering drug and administration costs. Additional cost-savings were achieved when the costs of FN-related hospitalizations related to PEG-OBI failure were taken into account. These cost-savings may potentially be reallocated to provide expanded access to additional cycles of PEG-jmdb or additional cycles of R-CHOP therapy.

Reference
McBride A, et al. ASH 2020. Abstract 3422.

 

Related Items


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: